All in all, dissecting the mechanisms underlying the dynamic interplay between estrogen/ER signaling, KRAS/STAT3 pathways in the lung tumor TME, which are poorly understood, may provide viable targets and strategies for personalizing targeted and immunotherapeutic modalities against K-ras mutant lung cancer (e.g. by sex). The gene discussed is STAT3; the disease is lung carcinoma.